You should contact your healthcare provider if you experience: Persistent or severe gastrointestinal symptoms that do not improve after the initial adjustment period, particularly if they interfere with nutrition or hydration Signs of pancreatitis : Severe, unrelenting abdominal pain, especially if radiating to the back, accompanied by nausea or vomiting Gallbladder problems : Upper right abdominal pain, fever, or yellowing of the skin or eyes Symptoms of hypoglycaemia : Frequent episodes of low blood sugar, particularly if you are also taking insulin or sulfonylureas New or worsening bowel symptoms : Persistent changes in bowel habit, rectal bleeding, unexplained weight loss, abdominal pain, or iron-deficiency anaemiathese warrant investigation regardless of medication use Concerns about cancer risk : If you have a strong family history of colorectal cancer or other risk factors, discuss personalised screening and prevention strategies Your GP can: Review your medication regimen and adjust doses or consider alternative treatments if side effects are problematic Arrange appropriate investigations , such as blood tests, faecal immunochemical testing (FIT), or referral for colonoscopy if red flag symptoms are present (in line with NICE guidance NG12 and DG30) Provide evidence-based reassurance about medication safety, drawing on MHRA guidance and clinical trial data Coordinate care with diabetes specialist teams and gastroenterology services when needed Discuss contraception and pregnancy planning if relevant, as semaglutide is not recommended during pregnancy or breastfeeding Do not stop taking Ozempic abruptly without medical advice, as this may lead to deterioration in blood glucose control

Although you can manage these side effects at home, in the event that they worsen or if your body has an allergic reaction to tirzepatide, let us know right away
Find out if Hershey's Special Dark Chocolate bar is better than other dark chocolate bars or cocoa powders, including flavanol content, contamination with lead or cadmium and other tests of quality
FOXO4-DRI is not approved by the U.S
Strengths and Limitations: One of the strengths of this study is in the diversity of their participants as 19% reported their race as Black and 26% reported their ethnic group as Hispanic or Latino, which is representative of the US population living with obesity